|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
A retrospective cohort study
1 Policy Analysis, Brookline, Massachusetts
2 Division of Endocrinology, School of Medicine, Emory University, Atlanta, Georgia
Address correspondence and reprint requests to Thomas E. Delea, MBA, Policy Analysis, 4 Davis Ct., Brookline, MA 02445. E-mail: tdelea{at}pai2.com
OBJECTIVE—To compare the incidence of heart failure in individuals with type 2 diabetes receiving thiazolidinediones (TZDs) versus other oral antihyperglycemic agents.
RESEARCH DESIGN AND METHODS—We conducted a retrospective cohort study using a health insurance claims database. The study sample included patients with type 2 diabetes who received an oral antihyperglycemic agent between January 1995 and March 2001. Those with any claims for TZDs were designated "exposed," and each was compared with five randomly selected unexposed patients. Those with diagnoses of heart failure or who received digoxin or a diuretic in the year before their index date were excluded. The primary measure of interest was incidence of heart failure, which was defined as a hospitalization or outpatient visit with a diagnosis of heart failure.
RESULTS—TZD patients (n = 5,441) were younger than control subjects (n = 28,103) but more likely to have coronary artery disease or diabetes complications, receive ACE inhibitors, ß-blockers, metformin, or insulin, and have undergone HbA1c tests or eye exams; they also had more comorbidities and higher costs (all P < 0.05). However, TZD use was predictive of heart failure even after controlling for these variables (hazard ratio = 1.7, P < 0.001). Adjusted incidence of heart failure at 40 months was 8.2% for TZD patients and 5.3% for control subjects.
CONCLUSIONS—The results of this observational study suggest that TZDs may increase the risk of heart failure. Physicians should use TZDs with caution in patients with heart failure, remain vigilant for manifestations of heart failure in those receiving these drugs (especially patients with cardiovasculopathy), and consider alternate therapies for patients who develop symptoms of heart failure, such as shortness of breath.
Abbreviations: AGI, 
-glucosidase inhibitor • CAD, coronary artery disease • SU, sulfonylurea • TZD, thiazolidinedione
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Lipscombe, T. Gomes, L. E. Levesque, J. E. Hux, D. N. Juurlink, and D. A. Alter Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes JAMA, December 12, 2007; 298(22): 2634 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann, B. Charbonnel, R. G. Wilcox, A. M. Skene, M. Massi-Benedetti, J. Yates, M. Tan, R. Spanheimer, E. Standl, J. A. Dormandy, et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08) Diabetes Care, November 1, 2007; 30(11): 2773 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T Eurich, F. A McAlister, D. F Blackburn, S. R Majumdar, R. T Tsuyuki, J. Varney, and J. A Johnson Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review BMJ, September 8, 2007; 335(7618): 497 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singh, Y. K. Loke, and C. D. Furberg Thiazolidinediones and Heart Failure: A teleo-analysis Diabetes Care, August 1, 2007; 30(8): 2148 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF]
|
|
|
|
|
|
D. Aguilar, B. Bozkurt, A. Pritchett, N. J. Petersen, and A. Deswal The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure J. Am. Coll. Cardiol., July 3, 2007; 50(1): 32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Karalliedde, R. Buckingham, M. Starkie, D. Lorand, M. Stewart, G. Viberti, and for the Rosiglitazone Fluid Retention Study Group Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3482 - 3490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Allen, F. Zhang, S. A. Moodie, L. E. Clemens, A. Smith, F. Gregoire, A. Bell, G. E.O. Muscat, and T. A. Gustafson Halofenate Is a Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulator With Antidiabetic Activity Diabetes, September 1, 2006; 55(9): 2523 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hiralal, K. K.Y. Koo, and H. C. Gerstein Does pioglitazone prevent macrovascular events in patients with type 2 diabetes? Can. Med. Assoc. J., April 11, 2006; 174(8): 1090 - 1091. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kendall Thiazolidinediones: The case for early use Diabetes Care, January 1, 2006; 29(1): 154 - 157. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy Selling Safety--Lessons From Muraglitazar JAMA, November 23, 2005; 294(20): 2633 - 2635. [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzales, T. Yang, C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, et al. Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers--Excess Sodium Reabsoption in the Collecting Duct: Collecting Duct-Specific Deletion of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Thiazolidinedione-Induced Fluid Retention. Proc Nat Acad Sci U S A 102: 9406-9411, 2005 J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3139 - 3142. [Full Text] [PDF]
|
|
|
|
|
|
R. I. Misbin Evaluating the Safety of Diabetes Drugs: Perspective of a Food and Drug Administration insider Diabetes Care, October 1, 2005; 28(10): 2573 - 2576. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study Circulation, February 8, 2005; 111(5): 583 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Maru, G. G. Koch, M. Stender, D. Clark, L. Gibowski, H. Petri, A. D. White, and R. J. Simpson Jr. Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting Diabetes Care, January 1, 2005; 28(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M Vivian, S. V Olarte, and A. M Gutierrez Insulin Strategies for Type 2 Diabetes Mellitus Ann. Pharmacother., November 1, 2004; 38(11): 1916 - 1923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity Hypertension, May 1, 2004; 43(5): 993 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Delea, J. S. Edelsberg, M. Hagiwara, G. Oster, and L. S. Phillips Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study: Response to Karter et al. Diabetes Care, March 1, 2004; 27(3): 852 - 853. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Karter, A. T. Ahmed, J. Liu, H. H. Moffet, M. M. Parker, A. Ferrara, and J. V. Selby Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes: A Retrospective Cohort Study: Response to Delea et al. Diabetes Care, March 1, 2004; 27(3): 850 - 851. [Full Text] [PDF]
|
|
|
|
 |
|
 Glitazone Drugs and Heart Failure -- Be Careful Journal Watch Gastroenterology, January 7, 2004; 2004(107): 7 - 7. [Full Text]
|
|
|
|
|
|
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A consensus statement from the American Heart Association and American Diabetes Association Diabetes Care, January 1, 2004; 27(1): 256 - 263. [Full Text] [PDF]
|
|
|
|
 |
|
 Glitazone Drugs and Heart Failure -- Be Careful Journal Watch Cardiology, December 19, 2003; 2003(1219): 6 - 6. [Full Text]
|
|
|
|
|
|
R. W. Nesto, D. Bell, R. O. Bonow, V. Fonseca, S. M. Grundy, E. S. Horton, M. Le Winter, D. Porte, C. F. Semenkovich, S. Smith, et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association Circulation, December 9, 2003; 108(23): 2941 - 2948. [Full Text] [PDF]
|
|
|
|
 |
|
 Glitazone Drugs and Heart Failure -- Be Careful Journal Watch (General), November 18, 2003; 2003(1118): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |